This clinical trial evaluates a type of scan called diffusion basis spectrum imaging (DBSI) for assessing the microenvironment tumor effects of treatment in patients with cervical or pancreatic cancer undergoing radiation therapy. A tumor microenvironment is the normal cells, molecules, and blood vessels that surround and feed a tumor cell. A tumor can change its microenvironment, and the microenvironment can affect how a tumor grows and spreads. DBSI is a type of imaging that takes place in an magnetic resonance imaging (MRI) scanner. An MRI takes pictures of the inside of the body by sending out a magnetic field and radio waves. DBSI may help to identify changes in the treatment area and how treatment affects patients with cervical or pancreatic cancer.
Additional locations may be listed on ClinicalTrials.gov for NCT05975593.
Locations matching your search criteria
United States
Missouri
Saint Louis
Siteman Cancer Center at Washington UniversityStatus: Active
Contact: Clifford G. Robinson
Phone: 314-362-8567
PRIMARY OBJECTIVE:
I. To prospectively evaluate changes in the tumor microenvironment through collection of longitudinal biospecimen and multimodal clinical data for patients undergoing radiotherapy for the treatment of locally advanced cervical cancer or locally advanced pancreatic cancer.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
CERVICAL CANCER COHORT: Patients undergo DBSI prior to start of radiation therapy (RT), 12 weeks after completing RT and at recurrence. Patients also undergo positron emission tomography (PET)/MRI, tumor tissue and blood sample collection throughout the study.
PANCREATIC CANCER COHORT: Patients undergo DBSI prior to start of RT, 12 weeks after completing RT and at recurrence. Patients also undergo PET/MRI, tumor tissue and blood sample collection throughout the study. Patients may also undergo additional sample collection at the time of surgery.
After completion of intervention, patients are followed up to 5 years.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationSiteman Cancer Center at Washington University
Principal InvestigatorClifford G. Robinson
